Establishment of a cynomolgus macaque model of influenza B virus infection  by Kitano, Mitsutaka et al.
Virology 407 (2010) 178–184
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roEstablishment of a cynomolgus macaque model of inﬂuenza B virus infection
Mitsutaka Kitano a,b, Yasushi Itoh a,⁎, Makoto Kodama b, Hirohito Ishigaki a, Misako Nakayama a,
Tomoya Nagata a, Hideaki Ishida a, Hideaki Tsuchiya c, Ryuzo Torii c, Keiko Baba b, Ryu Yoshida b,
Akihiko Sato b, Kazumasa Ogasawara a
a Department of Pathology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan
b Infectious Diseases, Medicinal Research Laboratories, Shionogi & Co., Ltd., Osaka 566-0022, Japan
c Research Center for Animal Life Science, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan⁎ Corresponding author. Department of Pathology,
Science, 485 Setatsukinowa, Otsu, Shiga 520-2192, Japa
E-mail address: yasushii@belle.shiga-med.ac.jp (Y. It
0042-6822/$ – see front matter © 2010 Elsevier Inc. A
doi:10.1016/j.virol.2010.08.006a b s t r a c ta r t i c l e i n f oArticle history:
Received 25 May 2010
Returned to author for revision 15 June 2010
Accepted 5 August 2010




Non-human primatePathogenicity of inﬂuenza B virus was examined in cynomolgus macaques to establish a macaque model
suitable for vaccine and antiviral drug development. We prepared inﬂuenza B viruses for inoculation with
minimal passages after isolation from patients. Macaques inoculated with inﬂuenza B virus showed higher
body temperature than that before infection for 6 to 12 days. Virus was detected in nasal, tracheal, and
bronchial samples until 6 days after inoculation followed by an increase in neutralizing antibody. High levels
of IL-6 and TNF-α in nasal swabs from the infected macaques were correlated with fever. Symptoms and
duration of the viral replication would be sufﬁcient to evaluate efﬁcacy of vaccines and antiviral agents. In
addition, measurement of immune responses including antibody and cytokine production would provide an
immunological rationale in efﬁcacy of vaccines and antiviral agents. The results suggest that cynomolgus
macaques are appropriate model animals for research of inﬂuenza B virus.Shiga University of Medical
n. Fax: +81 77 548 2423.
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Seasonal inﬂuenza virus epidemics occasionally cause severe acute
respiratory diseases and are major causes of morbidity and mortality
worldwide. Although both inﬂuenza A and B viruses are important in
human diseases, inﬂuenza B virus infection has attracted less attention
than inﬂuenza A virus infection for the following reasons. Firstly,
inﬂuenza A virus consistently appears almost every year, whereas the
appearance of inﬂuenza B virus is variable season by season (Kawai
et al., 2006; Skowronski et al., 2009). Secondly, inﬂuenza B viruses are
infrequently dominant circulating strains and their excess mortality
rates are generally less than those of inﬂuenza A viruses (Reichert
et al., 2004; Simonsen et al., 2000). Thirdly, in contrast to inﬂuenza A
viruses, which infect a broad range of animal species, inﬂuenza B
viruses exhibit a limited host range (Osterhaus et al., 2000). However,
clinical symptoms caused by seasonal inﬂuenza A and B infections are
indistinguishable, and signiﬁcant morbidity including inﬂuenza B
virus-associated encephalitis is complained during inﬂuenza B virus
epidemics (Hatakeyama et al., 2007; Lee et al., 2009; Newland et al.,
2003; Peltola et al., 2003). In addition, it has been reported that
inﬂuenza B virus was isolated more frequently and for a longer period
after antiviral therapy than was inﬂuenza A virus (Kawai et al., 2007).
Furthermore, it is also anticipated that inﬂuenza B virus epidemicswould not disappear after pandemics of 2009 H1N1 virus with a large
reduction of “Russian H1N1” and “Hong Kong H3N2” inﬂuenza A virus
cases (Nerome et al., 1998; McCullers et al., 2004; WHO, 2010).
Therefore, further developments of vaccines and antiviral drugs
against inﬂuenza B virus are required.
A mouse model of inﬂuenza virus infection is widely used as a
powerful tool for studying disease pathogenesis and evaluating
therapeutic and prophylactic strategies because of its predictability
and convenience for use. However, symptoms and immune responses
in mice are different from those in humans. For example, mice show
decreases in body temperature instead of fever after inoculation of
inﬂuenza virus (Conn et al., 1995; Van Reeth, 2000). In addition, mice
that have recovered from infection with an inﬂuenza A virus are
protected against challenge infection by other subtype viruses
(Webster and Askonas, 1980), whereas heterosubtypic responses
are weak in humans (Lynch et al., 2009). Therefore, pathogenicity
observed in mouse models may not directly extrapolate to humans. In
addition, since inﬂuenza B viruses are not natural pathogens for mice,
mouse-adapted viruses are used for research (McCullers et al., 2005).
On the other hand, ferrets are considered to be an appropriate host
model since ferrets show symptoms similar to those in human
patients suffering from inﬂuenza virus infection and a similar pattern
of viral replication (Govorkova et al., 2005; Sweet and Smith, 1980).
However, the ferret model has limitations including lack of available
immunological reagents for analyzing immune responses against
inﬂuenza viruses. Therefore, the purpose of the present study was to
establish an animal model for analysis of the pathogenicity of
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infection.
In contrast to small animal models, macaque monkeys, which are
genetically related to humans, are likely to be excellent animals for
analysis of inﬂuenza infection and immune system.Macaquemonkeys
have recently been used to characterize innate and adaptive immune
responses to inﬂuenza A virus infection (Baas et al., 2006; Baskin et al.,
2007, 2009). In addition, the levels and kinetics of viral replication and
the antiviral immune responses in macaques are almost the same as
those in experimentally infected humans (Carroll et al., 2008).
Furthermore, previous data from our laboratory demonstrated that
cynomolgus macaques enable analysis of the pathogenicity of highly
pathogenic avian inﬂuenza viruses and pandemic (H1N1) 2009
inﬂuenza virus (Itoh et al., 2008, 2009, 2010). However, to our
knowledge, there has been no study in which the pathogenicity of
seasonal inﬂuenza B virus in cynomolgus macaques was investigated.
Therefore, we examined the pathogenicity of seasonal inﬂuenza B
virus in cynomolgus macaques. We selected two seasonal inﬂuenza B
viruses, B/SendaiH/1051/2007 and B/Kadoma/1/2005, from various
clinical isolates, since these strains exhibited more potent virus
replication and induction of high temperature in the ferret model
than did other strains (manuscript in preparation). In order to gain a
better understanding of the pathogenesis and propagation of seasonal
inﬂuenza B virus in the cynomolgus macaque model from inoculation
with virus to recovery from disease, we examined not only severity of
clinical symptoms and duration of virus detection but also production
of cytokines, which would be caused by the host immune system
against virus infection.
In the present study, we found that seasonal inﬂuenza B virus
replicated especially in the upper respiratory tract of cynomolgus
macaques and that it induced pneumonitis and production of
inﬂammatory cytokines and chemokines. We also found a positive
correlation between kinetics of cytokine elaboration and virus
replication. These results are similar to experimental inﬂuenza
infection in humans initiated by nasal inoculation, which would not
be ethically allowed (Fritz et al., 1999; Hayden et al., 1998). Therefore,
inﬂuenza virus infection in cynomolgus macaques should be an
effective tool for preclinical study to evaluate the efﬁcacy of vaccines
and antiviral agents.
Results
Virus replication and clinical signs in cynomolgus macaques infected
with seasonal inﬂuenza B viruses
Initially, we examined the virus infectivity titers in swab ﬂuids and
bronchial brush samples from macaques inoculated with seasonal
inﬂuenza B virus, B/SendaiH/1051/2007 or B/Kadoma/1/2005.
Cytopathic effects (CPE) were detected in the culture of diluted
nasal swab ﬂuids from all macaques inoculated with either virus for a
period of 4 to 7 days after inoculation of virus, but no virus was
detected on day 8 after infection. On the other hand, in 6 of the 7
macaques (except #603), the viruses were also detected in tracheal
swabs and/or bronchial brush samples and the virus titers in tracheal
swabs and/or bronchial brush samples except in samples from #614
on days 4 and 5 were lower than those in nasal swabs (Fig. 1A). No
virus was detected in conjunctiva, rectal and blood samples (data not
shown). These ﬁndings indicate that the main location of virus
replication was the upper respiratory tract, especially nasal cavity.
Furthermore, viral propagation in the nasal swabs was followed by
that in tracheal and bronchial samples in #614, 795, 608, and 403.
These results suggested that the virus mainly replicating in the nasal
cavity spread to the trachea and bronchus.
Viral replication in the upper respiratory tract of macaques was
conﬁrmed by real-time quantitative polymerase chain reaction (PCR).
Inﬂuenza B virus genes were detected in swab samples of macaquesinfected with B/SendaiH/1051/2007 or B/Kadoma/1/2005 until day
8 (Fig. 1B). The copy number of the virus RNA in nasal swab samples
was higher than that in tracheal and bronchial samples. In addition,
viral RNA in nasal swab samples was detected for a longer period than
those in tracheal and bronchial samples. These results support the
data obtained from virus titration using Madin Darby Canine Kidney
(MDCK) cells that inﬂuenza B virus replicated mainly in the nasal
cavity of macaques.
Body temperature was expressed by calculating the average of the
highest and lowest temperatures during 1 day, and the body
temperature after the virus challenge was compared with that before
the virus challenge (Fig. 2). Higher body temperature than that before
the challenge was observed for 8 to 12 days after inoculation in
macaques infected with B/SendaiH/1051/2007 (#614, #794, #564
and #795) and for 6 to 12 days in macaques infected with B/Kadoma/
1/2005 (#608 and #403). However, the body temperatures returned
to the pre-infection level by the end of the experiment, except in
#794, which showed slightly high body temperature on day 13.
Interestingly, although viral propagation in #603 was observed only
in nasal swabs until day 5, increase of body temperature was not
clearly observed. Virus titer might be under the threshold level of high
body temperature in #603 and over the threshold level in other
macaques. Altogether these ﬁndings suggested that the extent of viral
propagation seemed to be related to severity of symptoms.
All macaques infected with B/SendaiH/1051/2007 lost appetite
after virus inoculation (Fig. 3). On the other hand, appetite and body
weight of macaques infected with B/Kadoma/1/2005 did not change
after the challenge. The average percent weights after infection
(weight on day 14/weight on day 0) were 95.5% and 97.0% in
macaques inoculated with B/SendaiH/1051/2007 and B/Kadoma/1/
2005, respectively. These ﬁndings suggested that B/SendaiH/1051/
2007 is more pathogenic than B/Kadoma/1/2005 in cynomolgus
macaques. No macaques used in the present study showed sneezing,
coughing or conjunctivitis after infection.
Antibody responses in cynomolgus macaques after infection with
inﬂuenza B viruses
Antibody responses against the viruses were examined in sera
from the infected macaques using hemagglutination inhibition (HI)
tests and neutralization tests. HI activities against B/SendaiH/1051/
2007 or B/Kadoma/1/2005 were observed in sera of macaques 6 days
after inoculation (Fig. 4). On the other hand, neutralization activity
was observed in 3 of 4macaques infectedwith B/SendaiH/1051/2007
and 2 of 3 macaques infected with B/Kadoma/1/2005 on day 6.
However, sera of all macaques showed neutralization activities on day
8. In addition, the titers reached plateaus on day 10 to 12 after
infection. These ﬁndings and data in Fig. 1 indicate that the macaques
infected with the seasonal inﬂuenza B virus induced immune
responses eliminating viruses in upper and lower respiratory tracts.
Inﬂammatory cytokine/chemokine responses in cynomolgus macaques
after infection with inﬂuenza B viruses
Production of inﬂammatory cytokines and chemokines in nasal
swabs was examined (Fig. 5). Levels of cytokines and chemokines
were increased after infection, but kinetics of cytokine and chemokine
production varied. Increase in production of IL-6 and TNF-α was
observed in all macaques. In addition, IL-6 production was correlated
with virus replication in nasal swabs as observed in swab samples of
#564 and #608, which displayed a biphasic increase in IL-6 levels and
viral titers on day 3 and day 6 after inoculation (Fig. 1). These ﬁndings
indicated that virus replication in the nasal cavity was responsible for
inducing IL-6 production. Furthermore, production of chemokines
MCP-1 and IL-8 was observed in nasal swabs. The MCP-1 production
pattern was similar to that of IL-6 and TNF-α, while IL-8 exhibited an
Fig. 1. Virus recovery from respiratory swabs of infected cynomolgus macaques. Cynomolgus macaques were inoculated with B/SendaiH/1051/2007 (left column) or B/Kadoma/1/
2005 (right column) on conjunctivas, into nasal cavities and tracheas. Nasal, tracheal, conjunctiva and rectal swabs and bronchial brush samples were collected on indicated days. (A)
Virus titers in swab samples were determined using MDCK cells. No virus was recovered from conjunctiva, rectal and blood samples or detected in any samples on days 8, 10 and 12.
Values of zero indicate that virus was not detected (detection limit: 1.4 log10 TCID50/ml). The numbers in upper right corners are animal identiﬁcation numbers. (B) The amount of
viral RNA in the swab samples was determined with real-time quantitative PCR.
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#403). In addition, 5 of 7 infected macaques (except #614 and #795)
exhibited a temporal increase in RANTES production in nasal swabs,
but RANTES production was not related to virus titers (Fig. 1).
The plasma levels of inﬂammatory cytokines and chemokines, IL-6,
TNF-α, MCP-1, IL-8 and RANTES, were also determined. IL-6, TNF-α
andMCP-1 were not detected during the course of the study, while IL-
8 and RANTES were detected, but the levels in plasma did not change
comparedwith the pre-infection levels (data not shown). The number
of white blood cells and CD4/CD8 ratio in blood samples obtained
from the infected macaques were also determined. However, no
signiﬁcant decrease in white blood cell concentration or CD4/CD8
ratio was observed (data not shown).
Pneumonitis in cynomolgus macaques after infection with inﬂuenza B
viruses
Histological changes in lung tissues obtained from the macaques
inoculated with inﬂuenza B viruses were assessed. All macaques were
autopsied 14 days after infection, and the lungs were ﬁxed in formalin
and then hematoxylin and eosin (H&E) staining was conducted. In the
lung of macaque #794 challenged with B/SendaiH/1051/2007,
mononuclear cell inﬁltration predominantly consisting of lympho-
cytes was observed (Fig. 6A, D). In addition, alveolar walls were
thickened by inﬁltration of inﬂammatory cells and granulation tissue
in the lung of macaque #608 challenged with B/Kadoma/1/2005(Fig. 6B, E). In contrast, no signiﬁcant thickness of alveolar walls and
inﬁltration of lymphocytes were observed in lung tissues of an
uninfected macaque (Fig. 6C, F). These results indicated that the
viruses infect alveolar epithelial cells in the macaque lungs and cause
viral interstitial pneumonia (pneumonitis).
We examined the presence of viral antigens in lung tissues 14 days
after challenge infection. A very few viral antigen-positive cells were
sparse only in bronchial epithelial cells of the macaques inoculated
with B/SendaiH/1051/2007 and B/Kadoma/1/2005 (Fig. 6G, H).
Inﬂuenza B virus antigen was not detected in the uninfected macaque
(Fig. 6I). These results indicate that viral antigens resided in bronchial
epithelial cells after elimination of live virus from swab samples.
Discussion
In the present study, we showed that seasonal inﬂuenza B virus
isolated from human patients replicated in the upper and lower
respiratory tracts of cynomolgus macaques and induced inﬂuenza
symptoms including fever. In addition, virus replication resulted in
increased production of inﬂammatory cytokines and chemokines in
nasal swabs. To our knowledge, this is the ﬁrst report demonstrating
pathogenicity of seasonal inﬂuenza B virus in cynomolgus macaques.
Animal models to investigate inﬂuenza B virus infection are limited
because of less severe morbidity than that of inﬂuenza A virus
infection in humans and lack of animal reservoirs (Osterhaus et al.,
2000; Simonsen et al., 2000). However, establishment of animal
Fig. 2. Body temperature change in infected cynomolgus macaques. On day 0,
cynomolgus macaques were inoculated with B/SendaiH/1051/2007 (left panels) or B/
Kadoma/1/2005 (right panels) on conjunctivas, into nasal cavities and tracheas. The
macaques' body temperatures were recorded every 15 min by telemetry probes
implanted into their peritoneal cavities. The plotted temperatures were calculated from
averages between highest temperatures and lowest temperatures recorded for the day.
Lines drawn horizontally indicated the averages of temperature levels during the pre-
infection period. The average durations of high temperature were 10.3 and 8.7 days in
macaques inoculated with B/SendaiH/1051/2007 and B/Kadoma/1/2005, respectively.
Fig. 4. Virus neutralization and hemagglutination inhibition (HI) activities of serum
samples after inoculation with inﬂuenza B virus. On day 0, cynomolgus macaques were
inoculated with B/SendaiH/1051/2007 (left panels) or B/Kadoma/1/2005 (right
panels). Sera were collected on the indicated days after infection with inﬂuenza B virus.
Diluted sera were incubated with 16 HA units of virus antigen for HI tests and 100
TCID50 of each virus for neutralization assays. HI titers were expressed as reciprocals of
the highest dilution at which samples completely inhibited hemagglutination (upper
panels). Neutralization titers were expressed as reciprocals of the highest dilution at
which samples showed complete neutralization (lower panels).
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the development and evaluation of vaccines and antiviral agents. In
the present study, viruses were recovered in nasal swabs for up toFig. 3. Body weight and food consumption of cynomolgus macaques inoculated with
seasonal inﬂuenza B virus. Appetite was reﬂected by the amount of food consumed,
which was calculated from the numbers of residual and fed pellets (upper graphs). The
percent body weight was calculated based on body weight measured on the indicated
days compared with weight before inoculation with virus (lower graphs).7 days post-infection and increased body temperature was observed
for 6 to 12 days after inoculation of inﬂuenza B virus. In addition,
neutralization and HI activities in sera were detected 6 to 8 days after
infection, concordant with decreasing virus titers in swab samples.
These results suggest that cynomolgus macaques can be used for a
model of inﬂuenza B virus infection as well as inﬂuenza A virus
infection including H5N1 and H7N7 highly pathogenic avian inﬂuenza
viruses and pandemic (H1N1) 2009 inﬂuenza virus (Itoh et al., 2008,
2009, 2010).
To investigate the pathogenesis of inﬂuenza B virus, it was
reported that animal-adapted viruses were generated by passage
through animals such as ferrets and mice rather than by culture in
eggs or tissue (Francis, 1940). In addition, nucleotide changes
accompanying amino acid changes were observed with altering
virulence during mouse adaptation (McCullers et al., 2005). Impor-
tantly, in the present study, cynomolgus macaques exhibited
symptoms and viral replication despite the use of viruses with
minimal passages in MDCK cells. Therefore, a cynomolgus macaque
model might be suitable for research in pathogenicity of clinical
strains of human inﬂuenza B virus.
In the present study, we determined the cytokine responses in
nasal swabs and plasma to investigate the relation between cytokine
responses and symptoms. The levels of IL-6, TNF-α and MCP-1 in the
nasal swabs were correlated with both virus replication and
symptoms. The peaks of IL-6 and TNF-α secretion were observed in
parallel, whereas the peaks of MCP-1 production showed a tendency
to follow those of IL-6 and TNF-α. These results are concordant with
results of previous studies using humans experimentally infected
with inﬂuenza virus showing that IL-6, TNF-α and MCP-1 were
released in response to inﬂuenza virus infection and that their plasma
concentrations were correlated with inﬂuenza-related symptoms
(Fritz et al., 1999; Hayden et al., 1998). However, we did not detect
increase in IL-6, TNF-α and MCP-1 levels in plasma. These ﬁndings
suggest that cytokines associated with inﬂuenza infection were
produced and consumed in the respiratory mucosa and therefore
did not enter circulation from the infected mucosa. Therefore, it is
speculated that mucosal IL-6 and TNF-α directly or indirectly induce
systemic symptoms in inﬂuenza virus infection.
The levels of the chemokine IL-8 were increased in nasal swab
samples after infection. IL-8 production observed in the nasal swabs of
macaques infected with B/SendaiH/1051/2007 was correlated with
Fig. 5. Inﬂammatory cytokine and chemokine responses in the ﬂuid of nasal swabs from infected cynomolgus macaques. The levels of various cytokines and chemokines in the ﬂuid
of nasal swabs from cynomolgus macaques infected with inﬂuenza virus B/SendaiH/1051/2007 (left panels) or B/Kadoma/1/2005 (right panels) were measured by the bead array
assay on the indicated days. IFN-γwas not detected in nasal swabs during the sampling period. The average levels of IL-6, TNF-α, MCP-1, IL-8 and RANTES in nasal swab samples from
seven other uninfected macaques were 17.2, 0.0, 6.6, 170.7 and 13.6 pg/ml, respectively.
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and TNF-α was observed in only one of the three macaques infected
with B/Kadoma/1/2005. This suggests that IL-8 production is
dependent on differences between B/SendaiH/1051/2007 and B/
Kadoma/1/2005. Furthermore, levels of RANTES did not change
during infection in macaque #614 and 795, whereas the other
macaques showed increase in RANTES secretion with no established
pattern. These ﬁndings suggest that inﬂuenza B viruses used in the
present study induce relatively mild symptoms and may not
effectively induce RANTES expression and that RANTES might have
little physiologic roles in inﬂuenza B infection.
In some cases, viral RNA in swab samples was detected by PCR
without observing live virus using MDCK cells. PCR may be more
sensitive to detect virus than titration using MDCK cells. In addition,
neutralization and HI activity of sera was observed on day 8 after
inoculation with virus when viral RNA in swab samples was detected
but live-virus titer was under a detection limit. On day 8, virus might
not be infectious since virus particles in swab ﬂuid were coated by
neutralizing antibody. Therefore, quantitative analysis of viral RNA is
thought to be useful to detect whole infectious and noninfectious
viruses in samples.
Taken together, our ﬁndings indicate that infection of cynomolgus
macaques with inﬂuenza B virus resulted in virus replication in the
upper respiratory tract and then induced inﬂammatory cytokine and
chemokineproduction in the nasal cavity. The levels and kinetics of viral
replication and antiviral immune responses in cynomolgus macaques
were similar to those of experimental human inﬂuenza infection. Thus,
cynomolgus macaques are suitable animals for studying the pathogen-
esis of inﬂuenza B virus including clinical strains and for evaluating
novel vaccines and drugs against inﬂuenza B virus.Materials and methods
Animals
Two- to ﬁve-year-old cynomolgus macaques (Macaca fascicularis)
from Vietnam were used with permission of the Shiga University of
Medical Science Animal Experiment Committee and Biosafety
Committee. In the text and ﬁgures, individual macaques are
distinguished by identiﬁcation numbers. Under anesthesia at least
twoweeks before virus inoculation, a telemetry probe (TA10CTA-D70,
Data Sciences International, St. Paul, MN) was implanted in the
peritoneal cavity of eachmacaque tomonitor body temperature every
15 min. The absence of inﬂuenza B-speciﬁc antibody in sera was
conﬁrmed before experiments using the HI test. Themacaques used in
this study did not carry B virus, hepatitis E virus, Mycobacterium
tuberculosis, Shigella spp., Salmonella spp., or Entamoeba histolytica. In
some experiments, samples from uninfectedmacaques were used as a
control.
Virus challenge
The seasonal inﬂuenza B viruses, B/SendaiH/1051/2007 and B/
Kadoma/1/2005, were kindly provided by Sendai Medical Center and
Osaka Prefectural Institute of Public Health, respectively. These
viruses were propagated twice in MDCK cells at 37 °C for 48 h for
production of virus stock. The macaques were inoculated with B/
SendaiH/1051/2007 (4×106 TCID50/5 ml) or B/Kadoma/1/2005
(1×107 TCID50/5 ml) on conjunctivas (50 μl/each eye) and into
nasal cavities (450 μl/each nostril) with a pipette and into the trachea








Fig. 6. Histological analysis of lung tissues obtained from infected cynomolgus macaques. Representative histopathological changes in lung tissues obtained from macaques
inoculated with inﬂuenza B virus and an uninfected macaque are shown. #794 and #608 were inoculated with B/SendaiH/1051/2007 (A, D and G) or B/Kadoma/1/2005 (B, E and
H), respectively. The macaques were autopsied 14 days after inoculation and lung tissues were recovered. Lung tissues of an uninfected macaque were stained as a negative control
(C, F and I). The lung tissues were examined with H & E staining and examined under low (A–C) and high (D–F) power magniﬁcation. The lung tissues were stained with sera from
mice infected with related inﬂuenza B virus (G–I). Viral antigen-positive cells were indicated with arrowheads.
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Tokyo, Japan) were used to collect swab ﬂuid samples in nasal
cavities, trachea, eyes, and rectum and the sticks were subsequently
immersed in 1 ml of PBS containing 0.1% BSA and antibiotics. A
bronchoscope (MEV-2560,Machida Endoscope Co., Ltd., Tokyo, Japan)
and brushes (BC-203D-2006, Olympus, Tokyo, Japan) were used to
collect bronchial samples. The brushes were quickly immersed in 1 ml
of PBS containing 0.1% BSA and antibiotics. Blood samples were
collected for measuring neutralizing antibody in sera. Collected
samples were stocked at a temperature below −80 °C until use.
Experiments using seasonal inﬂuenza B virus were performed in the
biosafety level 3 facility of the Research Center for Animal Life Science,
Shiga University of Medical Science.
For virus titration, serial dilutions of swab andwhole blood samples
were inoculated onto conﬂuent MDCK cells. After 1-h incubation, the
suspension was removed, and the cells were cultured in MEM
including 0.5% BSA and 3 μg/ml trypsin. The presence of CPE was
determined under a microscope 72 h later, and TCID50/ml was
calculated.
Viral RNA detection
Viral RNA was extracted from 140 μl of each swab ﬂuid, using the
QIAamp viral RNAminikit (Qiagen, Chatsworth, CA) and following the
manufacturer's instructions. The NP gene of inﬂuenza B virus was
chosen as the detection target (Smith et al., 2003). Primers and aprobe were synthesized by Operon Biotechnologies (Huntsville, AL)
and Applied Biosystems (Foster City, CA), respectively. The primers
for ampliﬁcation of the NP gene included forward primer, 5′-
AGAGTTGGACTTGAYCC-3′ and reverse primer 5′-CATAGG-
CAGTCTTGGCT-3′. The probe used for detection of inﬂuenza virus B
NP gene included 5′-AACTGGTGTTGCGATCAAAGGAGGTGG-3′, which
contained oligonucleotides with the 5′ reporter dye, 6-carboxyﬂuor-
escein (FAM), and the 3′ quencher dye, 6-carboxytetramethylrhoda-
mine (TAMRA). For real-time analysis, Platinum®Quantitative RT-PCR
ThermoScript™ One-Step System (Invitrogen, Carlsbad, CA) was
utilized for reverse transcription polymerase chain reaction (RT-
PCR). A 20 μl reaction mixture of real-time RT-PCR comprised 5 μl of
the puriﬁed RNA, 10 μl of 2× reaction mix, 0.4 μl of Rhodamine X
(ROX) as a passive reference dye, 0.4 μl of ThermoScript™ Plus/
Platinum® Taq Mix, 0.25 μM of the forward and reverse primers and
0.25 μMof the probe, and H2Owas added to bring up the ﬁnal volume.
The real-time RT-PCR was performed in the ABI Prism 7900 HT
sequence detection system (Applied Biosystems). The reverse
transcription reactions were performed at 50 °C for 30 min, followed
by 15 min at 95 °C to activate Platinum® DNA polymerase and then by
40 cycles of ampliﬁcation, including 15 s at 95 °C and 1 min at 60 °C.
The results were analyzed with SDS software version 2.2.2 (Applied
Biosystems). A standard curve was constructed by plotting each cycle
threshold (Ct) value against the log quantity of standard RNA copy
numbers. To obtain the amount of viral load present in each swab
ﬂuid, the test Ct value was extrapolated against the standard curve.
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Sera were treated with receptor destroying enzyme according to
the manufacturer's instruction (RDEII, Denka Seiken, Tokyo, Japan).
For HI testing, serially diluted sera were mixed with 16 HA units of
virus antigen for 1 h at room temperature. The mixture was then
incubated with 0.5% chicken red blood cells for 30 min at room
temperature. The HI titers were expressed as reciprocals of the
highest dilution of serum sample that completely inhibited hemag-
glutination. For the neutralization tests, diluted samples were mixed
with 100 TCID50 of B/Kadoma/1/2005 and B/SendaiH/1051/2007 for
1 h at room temperature. Then the mixture was inoculated onto
MDCK monolayers in 96-well tissue culture plates. After 1-h incuba-
tion, the suspension was removed, and the cells were covered with
MEM containing 0.5% BSA and 3 μg/ml trypsin without serum. After
incubation at 37 °C for 3 days, the presence of CPE was determined
under a microscope. The neutralization titers were expressed as
reciprocals of the highest dilution of serum sample that showed
complete neutralization.
Flow cytometry
Levels of inﬂammatory cytokines and chemokines (IL-6, IL-8, TNF-
α, IFN-γ, MCP-1 and RANTES) in nasal swab ﬂuids and plasma were
assessed using the Cytometric Bead Assay (Becton, Dickinson and
Company, Franklin Lakes, NJ) according to the manufacturer's
instructions. Results of assays were analyzed using FCAP Array
software (Becton, Dickinson and Company).
Histological examination
After autopsy, tissue samples ﬁxed with 10% formalin were
processed for H & E staining as described previously (Itoh et al.,
2008). For immunohistochemistry, tissues embedded in parafﬁnwere
sliced into 4-μm-thick section. Tissues were incubated with sera from
mice infected with inﬂuenza B virus B/SendaiH/1051/2007 or B/
Kadoma/1/2005 (1:100 dilution). The sections were then incubated
with horseradish peroxidase-conjugated anti-mouse IgG (Nichirei
Biosciences, Tokyo, Japan), followed by incubation with 3-3′-diami-
nobenzidine (DAB) (Nichirei Biosciences).
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